程序性死亡受体-1/程序性死亡配体-1抑制剂导致免疫相关甲状腺不良事件的研究进展  

Advances in research on immune-related adverse thyroid events caused by PD-1/PD-L1 inhibitors

作　　者：乔磊 胡玲[1] QIAO Lei;HU Ling(The Fifth Clinical Medical College of Shanxi Medical University,and The Department of Endocrinology of Shanxi Provincial People's Hospital,Taiyuan,Shanxi 030012,China)

机构地区：[1]山西医科大学第五临床医学院、山西省人民医院内分泌科,山西太原030012

出　　处：《安徽医药》2025年第3期456-459,共4页Anhui Medical and Pharmaceutical Journal

摘　　要：程序性死亡受体-1(PD-1)/程序性死亡配体-1(PD-L1)抑制剂是近年来用于抗肿瘤治疗的一种药物。其抗肿瘤效果是令人欣喜的,但其药物毒性和副作用也被相继报道,包括胃肠道、皮肤和内分泌腺体等免疫相关不良事件(irAEs)。其内分泌腺体损伤所致的不良事件可能危及生命,而免疫相关甲状腺不良事件(irTAEs)的发生率相对较高,该事件给病人带来二次打击的可能机制、危险因素以及对原发肿瘤预后的影响是目前研究的热点。因此该研究就该热点相关的国内外研究进展进行综述,为临床医师选用PD-1/PD-L1抑制剂、全面评估内分泌腺体功能以及在施用过程中及早识别irTAEs的发生提供参考。Programmed cell death receptor-1(PD-1)/programmed cell death ligand 1(PD-L1)inhibitors are drugs used in anti-tumor therapy in recent years.Its anti-tumor effect is fantastic,but its drug toxicity and side effects have also been reported,including immune-related adverse events(irAEs)in gastrointestinal tract,skin and endocrine glands.Adverse events caused by endocrine gland damage can be life-threatening,and the incidence of immune-related thyroid adverse events(irTAEs)is relatively high.The possible mechanism,risk factors and the influence on the prognosis of the primary tumor caused by these events are the focus of current researches.Therefore,this article reviews the domestic and foreign research progress related to this hot spot,providing reference for clinicians to use PD-1/PD-L1 inhibitors to comprehensively evaluate endocrine gland function and identify the occurrence of irTAEs as early as possible during administration.

关 键 词：免疫检查点抑制剂 程序性死亡受体-1 程序性死亡配体-1 免疫相关甲状腺不良事件 

分 类 号：R73[医药卫生—肿瘤]